https://hempgazette.com/news/neurotech-cannapacific-cannabis-hg1392/ 'CannaPacific will grow and maintain genetic stock and assist with varietal strains developed by NTI and Dolce Cann Global, from which NTI has an exclusive worldwide license to utilise. Early this month, Neurotech announced its licencing arrangements with Dolce Cann Global had been expanded from autism, epilepsy and ADHD to include all neurological disorders.'
Dec 2020 In December last year, Neurotech reported final results of in-vitro studies indicating its DOLCE/NTI cannabis strains exhibited potent anti-inflammatory activity. As well as potentially benefiting many patients, there’s big bucks to be made. Neurotech has quoted research forecasting the global market for neurology treatments is expected to grow to $39.4 billion by 2024. For its role in the partnership, CannaPacific will be issued 1,000,000 shares in Neurotech when an Office of Drug Control permit to produce NTI / Dolce cannabis strains for clinical trials is provided, then another 1,000,000 shares after delivery of the first harvest of dried flower, or by 1 August 2021 – whichever occurs first.
hope they didn't get flooded? just and FYI post ....apologies if posted previously somewhere
